Herbas VPB

Print
EN | LT
LT - (R)-3-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES
EN - (R)-3-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES

Legal status

Patent in force

Bibliographic data
Indications of the International Patent Classification (IPC)
(51) INT.CL. C07D 413/14 (2006.01)
A61K 31/4709 (2006.01)
A61K 31/5377 (2006.01)
A61K 31/4155 (2006.01)
A61K 31/4196 (2006.01)
A61K 31/422 (2006.01)
A61P 1/16 (2006.01)
A61P 5/00 (2006.01)
A61P 9/00 (2006.01)
A61P 11/00 (2006.01)
A61P 13/00 (2006.01)
A61P 13/12 (2006.01)
A61P 15/00 (2006.01)
A61P 17/00 (2006.01)
A61P 25/00 (2006.01)
European patent
(11) Number of the document 3956326
(13) Kind of document T
(96) European patent application number 20732117.5
Date of filing the European patent application 2020-05-25
(97) Date of publication of the European application 2022-02-23
(45) Date of publication and mention of the grant of the patent 2023-06-28
(46) Date of publication of the claims translation
PCT application
(86) Number PCT/EP2020/064379
Date 2020-05-25
PCT application publication
(87) Number WO 2020/234480
Date 2020-11-26
Priority applications
(30) Number Date Country code
19176229 2019-05-23 EP
Inventors
(72)
GIBSON, Christoph , DE
SAUPE, Joern , DE
AMBROSI, Horst-Dieter , DE
HAUSTEDT, Lars Ole , DE
Grantee
(73) Pharvaris GmbH , Grafenauweg 8, 6300 Zug, CH
Title
(54) (R)-3-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES
  (R)-3-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES